5.20
5.20 (0%)
As of Feb 14, 2025
Cara Therapeutics, Inc. [CARA]
Source:
Company Overview
Cara is a biopharmaceutical company that has been focused on leading a new treatment paradigm to improve the lives of patients suffering from chronic pruritus. Cara has developed an IV formulation of difelikefalin, which is approved for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis in the United States, the European Union, or EU, and multiple other countries.
| Country | United States |
| Headquarters | stamford, connecticut |
| Phone Number | 203-406-3700 |
| Industry | manufacturing |
| CEO | Christopher Posner |
| Website | www.caratherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $7.1 |
| Operating Profit | $-58.4 |
| Net Income | $-70.9 |
| Net Cash | $-15.8 |
Profit Ratios
| Gross Margin | $6.5 |
| Operating Margin | -818 |
| Profit as % of Revenues | -9.2% |
| Profit as % of Assets | -83.5% |
| Profit as % of Stockholder Equity | 1,542.9% |
Management Effectiveness
| Return on Equity | 1,542.9% |
| Return on Assets | -161.7% |
| Turnover Ratio | 8.4% |
| EBITA | $-58.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $43.8 |
| Total Liabilities | $48.4 |
| Operating Cash Flow | $-60.9 |
| Investing Cash Flow | $48.7 |
| Financing Cash Flow | $-3.6 |
